Partners to use AI, machine learning to test NX210c for Parkinson’s
InSilicoTrials and Axoltis Pharma are teaming up to conduct computer-based studies — using both artificial intelligence (AI) and machine learning — that will test the potential therapeutic effect of Axoltis’ treatment candidate NX210c on virtual patients with Parkinson’s disease and other neurological disorders. “We are thrilled to…